ASND

Premium Grower

Ascendis Pharma A/S · Healthcare · Denmark · $16.6B cap · $176.7M/day traded

$252.73 -1.3% · close 20 Nov · scored 21 Nov

Score up 1.0 since 20 Nov.

Premium Grower: Strong business with the market behind it, priced at a premium.

66
Score
Get score and insider alerts
Quality
76
Value
22
Momentum
65

As of 21 Nov 2026, the MoatMap Score for Ascendis Pharma A/S (ASND) is 66/100, ranked against 25,000+ stocks in 38 markets (Quality 76, Value 22, Momentum 65, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
16.6x
peers 26.0x
ROE
132.2%
peers 15.4%
D/E
0.3x
peers 0.3x
Dividend %
—
trailing yield

ABOUT ASCENDIS PHARMA A/S

Read

Ascendis Pharma A/S is a biopharmaceutical company focused on developing innovative prodrug therapies for rare diseases using its proprietary TransCon technology platform. Its competitive moat is derived from this unique and versatile technology, which enables the creation of sustained-release drug candidates with improved efficacy and safety profiles. The company is a specialized biotech firm, aiming to redefine standards of care for patients with significant unmet medical needs.

FINANCIAL SUMMARY (USD)

Reported in EUR

Year20212022202320242025CAGRTTM2026EFwd CAGR
Income and shares
Revenue9.2M53.9M288.5M393.6M813.9M206.7%1.3B1.5B91.5%
Net margin-4931.6%-1139.6%-180.5%-104.0%-31.7%+4899.9 pts———
EPS-8.3-11.0-9.2-7.1-4.2—15.2——
Share count54.8M57.2M56.6M59.8M61.4M2.9%65.6M——
Balance sheet
Debt—542.0M713.1M891.4M1.0B23.6%491.2M——
Equity1.0B280.7M-161.3M-110.0M-191.3M-71.9%———
Debt/equity—1.9xn/mn/mn/m————
Cash flow
Op. cash flow-494.2M-522.3M-505.6M-331.4M60.9M—588.1M——
Cash flow margin-5369.6%-968.7%-175.2%-84.2%7.5%+5377.1 pts44.6%——
Investing CF-130.8M65.0M309.9M7.4M-9.6M————
Financing CF415.8M418.1M145.3M480.5M41.1M————
PRICE (1Y) · USD+11.3%
22323624926227512 Oct2 Nov20 Nov
SMA 50SMA 200

Price checkIn an uptrendExperimental

Above its 200-day average and 10% below its 52-week high.

SwingsAverage

Calmer than 57% of stocks we rank over the past year (volatility 38% a year).

How this is worked out

The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.

  • Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
  • Finding a floor: It fell hard, but has set no new low for more than two weeks.
  • Turning up: It has climbed off its low and is back above a rising 50-day average.
  • In an uptrend (this stock): It is near its 52-week high and above its 200-day average.
  • No clear trend: None of the above: no recent deep fall and no steady climb.
  • No read yet: Not enough price history yet: it needs a year of trading.

In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.

The exact rules

Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
$252.73
RSI (14)
52.9
52-Week Range-10.4% from high
Low $188.08High $282.15

SCORE BREAKDOWN

Quality
76
ROIC
94.1%99.6
ROE
132.2%99.6
GP/Assets
82.4%96.5
Op. Margin
30.9%93.3
FCF/Assets
3.5%61.7
Piotroski
549.5
Int. Cover
1.8x41.2
D/E Ratio
0.30x41.2
Current Ratio
2.89x54.2
Value
22
P/E (TTM)
16.6x62.5
EV/EBITDA
38.8x12.2
P/FCF
323.1x3.8
P/B
9.0x9.8
P/S
12.6x19.1
Div Yield
—N/A
Momentum
65
52W High %
90%87.3
RS 6M
9%68.8
SMA 50/200
1.01x64.8
EPS Rev 4W
+12.3%93.0
EPS Rev 12W
+13.1%85.9
EPS Improve
-19%15.3
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$16.6B
P/E (Forward)
20.5x
Gross Margin
91.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ASND are excluded.

TickerCompanyMkt CapScore
ASNDAscendis Pharma A/S(you)$16.6B66
GMAB.COGenmab A/S$31.4B68
ALK-B.COALK-Abelló A/S$7.8B76
ZEAL.COZealand Pharma A/S$2.0B71
BAVA.COBavarian Nordic A/S$2.7B94
GUBRA.COGubra A/S$639M32
SANION.STSaniona AB (publ)$152M83
COLO-B.COColoplast A/S$16.4B88
DEMANT.CODemant A/S$10.7B79
GN.COGN Store Nord A/S$2.5B62

Peer medians: ROE 15.4% · P/E 26.0x · Gross margin 81.2%

Company Deep Dive

A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

Request Deep Dive(50 Feathers)

Ascendis Pharma A/S (ASND): Stock Score Summary

Ascendis Pharma A/S (ASND) has a MoatMap Score of 66/100 based on Quality (76/100), Value (22/100), and Momentum (65/100) factor scores.

Ascendis Pharma A/S is a biopharmaceutical company focused on developing innovative prodrug therapies for rare diseases using its proprietary TransCon technology platform. Its competitive moat is derived from this unique and versatile technology, which enables the creation of sustained-release drug candidates with improved efficacy and safety profiles. The company is a specialized biotech firm, aiming to redefine standards of care for patients with significant unmet medical needs.

Director dealings

From 22 Nov 2025 to 20 Nov 2026, MoatMap's records hold 4 sales and 5 purchases of Ascendis Pharma A/S (ASND) shares by its directors. The largest: PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG sold 20,000 shares at $263.89 on 17 Nov 2026 (about $5.3M).

  • 17 Nov 2026: PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG sold 20,000 shares at $263.89 (about $5.3M)
  • 8 Sep 2026: Bodenhoff Mads sold 3,000 shares at $270.19 (about $811K)
  • 2 Sep 2026: HOLTUG LARS sold 236 shares at $264.13 (about $62K)
  • 14 Aug 2026: BIENAIME JEAN JACQUES bought 2,000 shares at $246.33 (about $493K)
  • 2 Jun 2026: SMITH SCOTT THOMAS bought 100 shares at $219.00 (about $22K)
ASND insider filings, last 180 days

Key Financial Metrics

Price$252.73
Market Cap$16.6B
P/E (TTM)16.62
P/E (Forward)20.47
Price/Book8.97
Return on Equity132.2%
Return on Invested Capital94.1%
Debt/Equity0.30x
Gross Margin91.9%
Operating Margin30.9%
Revenue Growth73.0%
Free Cash Flow$51M

Ascendis Pharma A/S operates in the Biotechnology industry, part of the Healthcare sector (Denmark).

Frequently Asked Questions

What is Ascendis Pharma A/S’s (ASND) MoatMap Score?
The MoatMap Score for Ascendis Pharma A/S (ASND) is 66/100. It is a composite of Quality (76), Value (22), and Momentum (65), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does Ascendis Pharma A/S have an economic moat?
Ascendis Pharma A/S (ASND) has a Quality factor score of 76/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is Ascendis Pharma A/S in?
Ascendis Pharma A/S (ASND) operates in the Healthcare sector, specifically the Biotechnology industry (Denmark).